Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Thomas Tu"'
Publikováno v:
Nature Reviews Gastroenterology & Hepatology. 17:618-634
The global burden of hepatitis B virus (HBV) is enormous, with 257 million persons chronically infected, resulting in more than 880,000 deaths per year worldwide. HBV exists as nine different genotypes, which differ in disease progression, natural hi
Autor:
Yuanyuan Liu, Vaishnavi Veeraraghavan, Monica Pinkerton, Jianjun Fu, Mark W. Douglas, Jacob George, Thomas Tu
Publikováno v:
Frontiers in Microbiology
Frontiers in Microbiology, Vol 12 (2021)
Frontiers in Microbiology, Vol 12 (2021)
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the fourth leading cause of cancer-related death. The most common risk factor for developing HCC is chronic infection with hepatitis B virus (HBV). Early stages of HBV-relat
Autor:
Geoffrey C. Farrell, W. d’Avigdor, Susan V. McLennan, M Stapelberg, M. Lee, Geoffrey W. McCaughan, Thomas Tu, Magdalena A. Budzinska, James G. Kench, Nicholas A. Shackel, R Lam, Jacob George
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports
Scientific Reports
Despite advances in antiviral therapy, molecular drivers of Hepatitis C Virus (HCV)-related liver disease remain poorly characterised. Chronic infection with HCV genotypes (1 and 3) differ in presentation of liver steatosis and virological response t
Autor:
Robert Maholic, Tod C. Engelhardt, Christopher Adams, Glenn Hoots, Monica Hunter, Scott Lilly, Mitchell J. Silver, Mitchell Weinberg, Flare Investigators, David R. Holmes, Thomas Tu, Kenneth Ouriel, Hussam Hamdalla, Wissam Jaber, Catalin Toma, Sameer Khandhar, Rohit Amin, Kenneth Rosenfield, Victor F. Tapson
Publikováno v:
JACC: Cardiovascular Interventions. 12:859-869
Objectives: The aim of this study was to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the FlowTriever System (Inari Medical, Irvine, California) in a ...
Publikováno v:
Viruses
Viruses, Vol 12, Iss 515, p 515 (2020)
Viruses, Vol 12, Iss 515, p 515 (2020)
Chronic hepatitis B (CHB) is one of the most widespread liver diseases in the world. It is currently incurable and can lead to liver cirrhosis and cancer. The considerable impacts on society caused by CHB through patient mortality, morbidity, and eco
Autor:
Nicholas A. Shackel, Thomas Tu, Magdalena A. Budzinska, Katherine Bryant, Kevin J. Spring, Scott D. Collins, Gloria S‐c Yuen
Publikováno v:
Hepatocellular Carcinoma ISBN: 9780994438188
In vitro models of the liver have led to important insights into the pathogenesis of liver disease. These models are essential tools in the discovery and preclinical stages of drug development. The clinical application of these models is also emergin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a77246606a89b0d23d1f4858ddc3adc
https://doi.org/10.15586/hepatocellularcarcinoma.2019.ch3
https://doi.org/10.15586/hepatocellularcarcinoma.2019.ch3
Autor:
Peter Schemmer, Ralf Bartenschlager, Georgios Polychronidis, A Restuccia, Katrin Hoffmann, Benjamin Schusser, Ronald Koschny, K Schöneweis, Philippe Metz, Florian A. Lempp, Stephan Urban, Pascal Mutz, Jamie Frankish, Thomas F. Baumert, Silke Bender, Marco Binder, Stefan Seitz, Thomas Tu, Bingqian Qu
Publikováno v:
Zeitschrift für Gastroenterologie. 56:E2-E89
Publikováno v:
Applied Energy. 205:453-464
Appliance energy-efficiency programs are a central component of many countries’ energy-policy portfolios. A major barrier to optimal implementation of these programs is lack of data to determine market baselines, assess the potential for cost-effec
Publikováno v:
Biological Chemistry. 398:817-837
Chronic infection with hepatitis viruses represents the major causative factor for end-stage liver diseases, including liver cirrhosis and primary liver cancer (hepatocellular carcinoma, HCC). In this review, we highlight the current understanding of
Autor:
Thomas Tu
Publikováno v:
JACC: Cardiovascular Interventions. 12:1744-1745
I thank Dr. Kaymaz and colleagues for their letter regarding the results of the FLARE study (FlowTriever Pulmonary Embolectomy Clinical Study) [(1)][1]. Several of their points are well taken. This is the first study to evaluate the safety and effica